Related Experiment Video
Updated: Jul 13, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of
Emmanuel T Akporiaye1, Deborah Bradley-Dunlop, Sandra J Gendler
1Department of Immunobiology, The University of Arizona, Tucson, AZ 85724, USA. akporiay@email.arizona.edu
Abstract:
A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/(MIN/+) (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-gamma secretion by lymphocytes.
Insights
A novel MUC1 vaccine effectively reduced intestinal adenomas in mice by stimulating a targeted immune response. This immunotherapy shows promise for treating MUC1-expressing tumors.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Intestinal adenomas, often driven by genetic mutations like APC, are a precursor to colorectal cancer.
- The MUC1 antigen is frequently overexpressed in various cancers, making it a potential therapeutic target.
Purpose of the Study:
- To evaluate the efficacy of MUC1 antigen-specific immunotherapy in a MUC1.Tg/MIN mouse model of intestinal adenomas.
- To assess the immunogenicity and anti-tumor effects of a MUC1-based vaccine.
Main Methods:
- Development of a bigenic MUC1.Tg/MIN mouse model by crossing MUC1 transgenic mice with Apc/(MIN/+) mice.
- Administration of a MUC1-based vaccine composed of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, CpG oligodeoxynucleotide, and GM-CSF.
- Assessment of adenoma development, serum MUC1 levels, and immune responses, including anti-tumor cytotoxicity and IFN-gamma secretion.
Main Results:
- MUC1.Tg/MIN mice exhibited adenoma development and serum MUC1 levels comparable to MIN mice.
- The MUC1-based vaccine led to adenoma flattening and a significant reduction in large adenomas.
- Immunization successfully generated a MUC1-directed immune response, indicated by enhanced MUC1 peptide-specific anti-tumor cytotoxicity and increased IFN-gamma secretion.
Conclusions:
- MUC1 antigen-specific immunotherapy is a viable strategy for reducing intestinal adenomas.
- The developed MUC1-based vaccine is immunogenic and demonstrates therapeutic potential against MUC1-expressing tumors.
- This study provides a foundation for further investigation of MUC1-targeted cancer immunotherapies.
